Aclarion, Inc. (Nasdaq: ACON, ACONW) reported first quarter 2026 financial results highlighting a 196% year-over-year increase in Nociscan scan volumes, reflecting accelerating clinical adoption of its SaaS platform that helps physicians identify the source of chronic low back pain. The company also achieved 64% sequential growth from Q4 2025, driven by new account activations and deeper utilization within existing sites, signaling increasing integration into clinical workflows.
The strong performance underscores the growing acceptance of Nociscan, which analyzes magnetic resonance spectroscopy data using proprietary biomarkers and augmented intelligence algorithms. Each year, approximately 5.8 million lumbar MRIs are performed in the U.S. for low back pain, representing a large addressable market. Aclarion believes Nociscan can capture a potential $2 billion market opportunity as adoption expands.
Key catalysts for growth include early reimbursement successes in the U.K., where three of the four largest private insurers—Vitality, AXA, and Aviva—now cover Nociscan. The company also launched a targeted direct-to-patient campaign featuring Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic. In the U.S., Aclarion continues to engage payers through its Nociscan Reimbursement Program to establish coverage pathways.
On the clinical front, Aclarion is advancing the CLARITY randomized trial, designed to validate Nociscan's clinical utility in guiding treatment decisions. A preliminary internal readout is expected in the second half of 2026, with public disclosure of early interim results anticipated in late 2026. The company also has seven ongoing clinical trials and multiple investigator-initiated real-world evidence trials to support reimbursement discussions.
Aclarion strengthened its intellectual property portfolio with a newly issued patent covering the use of AI in workflows of future products, bringing its total to 64 issued and pending patents worldwide. The company maintains a strong financial position with $19.0 million in cash, no debt, and a clean capital structure. As of March 31, 2026, there were 2,444,871 common shares outstanding, or 2,882,371 on a fully diluted basis, representing approximately $6.60 per share in cash. A recently announced $2.5 million share repurchase program reinforces management's confidence in the company's growth trajectory. Based on current operating plans, Aclarion believes its cash resources are sufficient to fund operations into the second half of 2027.
“Q1 represents a clear inflection for Aclarion,” said Brent Ness, Chief Executive Officer. “Scan volume growth accelerated significantly, driven by increasing physician adoption and stronger execution with our recently hired Commercial Directors in the UK and the Eastern US. Importantly, we are still in the early stages of commercializing Nociscan into a large and underpenetrated market.”
More information is available on Aclarion's newsroom at https://tinyurl.com/aconnewsroom.
